{"transactions":[{"id":4621370,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-17T20:28:41.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":488801,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000015","document":"form4-09172026_080936.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000015/form4-09172026_080936.xml","form_type":"4"}},{"id":4621369,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-17T20:28:41.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":18500,"price":37,"value":684500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000015","document":"form4-09172026_080936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000015/form4-09172026_080936.xml","form_type":"4"}},{"id":4621368,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-17T20:28:41.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000015","document":"form4-09172026_080936.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000015/form4-09172026_080936.xml","form_type":"4"}},{"id":4616991,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-14T20:28:25.000Z","date":"2026-09-11","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter."}],"balance_after":33589,"derivative":{"exercise_price":3.9396,"expiration_date":"2031-04-13","underlying":"Class A Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001861684-26-000006","document":"form4-09142026_080921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000186168426000006/form4-09142026_080921.xml","form_type":"4"}},{"id":4616990,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Class A Common Stock","published_at":"2026-09-14T20:28:25.000Z","date":"2026-09-11","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":3.9396,"value":19698.0,"ownership":{"direct":true},"balance_after":80754,"source":{"system":"sec-edgar","filing":"0001861684-26-000006","document":"form4-09142026_080921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000186168426000006/form4-09142026_080921.xml","form_type":"4"}},{"id":4467,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T20:15:08.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":507301,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000014","document":"form4-09042026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000014/form4-09042026_040901.xml","form_type":"4"}},{"id":4466,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-04T20:15:08.000Z","date":"2026-09-02","kind":"sale","planned":true,"acquired":false,"shares":18500,"price":35.1158,"value":649642.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.34, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000014","document":"form4-09042026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000014/form4-09042026_040901.xml","form_type":"4"}},{"id":4465,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-09-04T20:15:08.000Z","date":"2026-09-02","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000014","document":"form4-09042026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1859453/000185945326000014/form4-09042026_040901.xml","form_type":"4"}},{"id":688777,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":46250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":525801,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":46250},"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688776,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":43.5947,"value":95908.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688775,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":10500,"price":42.8578,"value":450006.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":237444,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688774,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":32550,"price":42.0736,"value":1369495.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":247944,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688773,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":40.7762,"value":40776.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":280494,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688772,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:42:35.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":true,"shares":46250,"price":2.8968,"value":133977.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on July 7, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":281494,"source":{"system":"sec-edgar","filing":"0001859453-26-000013","document":"form4a-08122026_100831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000013/form4a-08122026_100831.xml","form_type":"4/A","original_submission_date":"2026-07-09"}},{"id":688768,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":572051,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688767,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":88,"price":38.43,"value":3381.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688766,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":18412,"price":37.9311,"value":698387.4132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235332,"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688765,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:41:34.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on June 23, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000012","document":"form4a-08122026_100823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000012/form4a-08122026_100823.xml","form_type":"4/A","original_submission_date":"2026-06-24"}},{"id":688764,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vested monthly thereafter."}],"balance_after":590551,"derivative":{"exercise_price":2.8968,"expiration_date":"2030-12-15","underlying":"Class A Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":688763,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":4281,"price":37.0868,"value":158768.5908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":688762,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":14219,"price":36.6396,"value":520978.4724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales were made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":239525,"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":688761,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-08-12T22:39:13.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":true,"shares":18500,"price":2.8968,"value":53590.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amended Form 4 is filed to reflect the option exercise that occurred on May 12, 2026 and correct the amounts reported in Column 5 \"Amount of Securities Beneficially Owned Following Reported Transaction(s)\"."}],"balance_after":253744,"source":{"system":"sec-edgar","filing":"0001859453-26-000011","document":"form4a-08122026_100809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000011/form4a-08122026_100809.xml","form_type":"4/A","original_submission_date":"2026-05-13"}},{"id":695057,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":26115,"kind":"person","name":"Boman Nancy Lee","position":1,"cik":"0002145711","reported_name":"Boman Nancy Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-08-05T20:14:06.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":63011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12/48ths of the shares subject to the stock option will vest and become exercisable on August 3, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":63011,"derivative":{"exercise_price":32.23,"expiration_date":"2036-08-02","underlying":"Class A Common Stock","underlying_shares":63011},"source":{"system":"sec-edgar","filing":"0002145711-26-000002","document":"form4-08052026_080802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000214571126000002/form4-08052026_080802.xml","form_type":"4"}},{"id":695056,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":26115,"kind":"person","name":"Boman Nancy Lee","position":1,"cik":"0002145711","reported_name":"Boman Nancy Lee","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2026-08-05T20:14:06.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":44987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2024 Inducement Plan. 1/4th of the RSUs, rounded to the nearest whole share, vest on each of August 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":44987,"source":{"system":"sec-edgar","filing":"0002145711-26-000002","document":"form4-08052026_080802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000214571126000002/form4-08052026_080802.xml","form_type":"4"}},{"id":711584,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":43.5947,"value":95908.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.42 to $43.97, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":151994,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":711583,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":10500,"price":42.8578,"value":450006.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.40 to $43.38, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":154194,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":711582,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":32550,"price":42.0736,"value":1369495.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.40 to $42.39, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":164694,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":711581,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-07-09T20:45:04.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":40.7762,"value":40776.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.39 to $41.31, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":197244,"source":{"system":"sec-edgar","filing":"0001859453-26-000010","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000010/form4-07092026_040701.xml","form_type":"4"}},{"id":727233,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-06-24T20:55:47.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":88,"price":38.43,"value":3381.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":198244,"source":{"system":"sec-edgar","filing":"0001859453-26-000008","document":"form4-06242026_080643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000008/form4-06242026_080643.xml","form_type":"4"}},{"id":727232,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-06-24T20:55:47.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":18412,"price":37.9311,"value":698387.4132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $37.43 to $38.315, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":198332,"source":{"system":"sec-edgar","filing":"0001859453-26-000008","document":"form4-06242026_080643.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000008/form4-06242026_080643.xml","form_type":"4"}},{"id":763212,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:24:18.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001662426-26-000002","document":"form4-05262026_080514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000166242626000002/form4-05262026_080514.xml","form_type":"4"}},{"id":763182,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:22:59.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001778307-26-000002","document":"form4-05262026_080555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1778307/000177830726000002/form4-05262026_080555.xml","form_type":"4"}},{"id":763455,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:22:04.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001184592-26-000002","document":"form4-05262026_080559.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000118459226000002/form4-05262026_080559.xml","form_type":"4"}},{"id":763171,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":276,"kind":"person","name":"Oliger Christy J.","position":1,"cik":"0001822092","reported_name":"Oliger Christy J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:20:52.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001822092-26-000005","document":"form4-05262026_080547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822092/000182209226000005/form4-05262026_080547.xml","form_type":"4"}},{"id":763350,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":16123,"kind":"person","name":"Meyers James R","position":1,"cik":"0001387521","reported_name":"Meyers James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:19:45.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001387521-26-000002","document":"form4-05262026_080541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387521/000138752126000002/form4-05262026_080541.xml","form_type":"4"}},{"id":764022,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":44273,"kind":"person","name":"Hall Kimball","position":1,"cik":"0001897965","reported_name":"Hall Kimball","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:18:33.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001897965-26-000002","document":"form4-05262026_080529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897965/000189796526000002/form4-05262026_080529.xml","form_type":"4"}},{"id":763444,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":44157,"kind":"person","name":"MORRISSEY MICHAEL","position":1,"cik":"0001202096","reported_name":"MORRISSEY MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:17:28.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001202096-26-000002","document":"form4-05262026_080523.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202096/000120209626000002/form4-05262026_080523.xml","form_type":"4"}},{"id":763434,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-05-26T20:15:26.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":17084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":17084,"derivative":{"exercise_price":34.35,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":17084},"source":{"system":"sec-edgar","filing":"0001253886-26-000004","document":"form4-05262026_080520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253886/000125388626000004/form4-05262026_080520.xml","form_type":"4"}},{"id":780276,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-05-13T20:26:47.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":4281,"price":37.0868,"value":158768.5908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $36.97 to $37.15, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":216744,"source":{"system":"sec-edgar","filing":"0001859453-26-000007","document":"form4-05132026_080543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000007/form4-05132026_080543.xml","form_type":"4"}},{"id":780275,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-05-13T20:26:47.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":14219,"price":36.6396,"value":520978.4724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.96 to $36.94, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":221025,"source":{"system":"sec-edgar","filing":"0001859453-26-000007","document":"form4-05132026_080543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000007/form4-05132026_080543.xml","form_type":"4"}},{"id":807939,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-04-15T20:57:38.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":900,"price":45.5114,"value":40960.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended,"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.25 to $45.67, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":235244,"source":{"system":"sec-edgar","filing":"0001859453-26-000006","document":"form4-04152026_080434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/form4-04152026_080434.xml","form_type":"4"}},{"id":807938,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-04-15T20:57:38.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":7921,"price":44.5784,"value":353105.5064,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $45.20, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":236144,"source":{"system":"sec-edgar","filing":"0001859453-26-000006","document":"form4-04152026_080434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/form4-04152026_080434.xml","form_type":"4"}},{"id":807937,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-04-15T20:57:38.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":14130,"price":43.6649,"value":616985.037,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made pursuant to a written plan adopted on January 9, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended,"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.24, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,032 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2026."}],"balance_after":244065,"source":{"system":"sec-edgar","filing":"0001859453-26-000006","document":"form4-04152026_080434.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000006/form4-04152026_080434.xml","form_type":"4"}},{"id":828039,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":56003,"kind":"person","name":"Wright-Mitchell Jane","position":1,"cik":"0001614568","reported_name":"Wright-Mitchell Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-25T19:08:28.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":56850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12/48ths of the shares subject to the stock option will vest and become exercisable on March 23, 2027, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":56850,"derivative":{"exercise_price":40.73,"expiration_date":"2036-03-22","underlying":"Class A Common Stock","underlying_shares":56850},"source":{"system":"sec-edgar","filing":"0001614568-26-000008","document":"form4-03252026_110324.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614568/000161456826000008/form4-03252026_110324.xml","form_type":"4"}},{"id":828038,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":56003,"kind":"person","name":"Wright-Mitchell Jane","position":1,"cik":"0001614568","reported_name":"Wright-Mitchell Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-25T19:08:28.000Z","date":"2026-03-23","kind":"grant","planned":false,"acquired":true,"shares":42403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of May 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":42403,"source":{"system":"sec-edgar","filing":"0001614568-26-000008","document":"form4-03252026_110324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614568/000161456826000008/form4-03252026_110324.xml","form_type":"4"}},{"id":841815,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-16T18:52:14.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter."}],"balance_after":38589,"derivative":{"exercise_price":3.9396,"expiration_date":"2031-04-13","underlying":"Class A Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001861684-26-000005","document":"form4-03162026_100309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000186168426000005/form4-03162026_100309.xml","form_type":"4"}},{"id":841814,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Class A Common Stock","published_at":"2026-03-16T18:52:14.000Z","date":"2026-03-13","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":3.9396,"value":39396.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,032 shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan."}],"balance_after":75754,"source":{"system":"sec-edgar","filing":"0001861684-26-000005","document":"form4-03162026_100309.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000186168426000005/form4-03162026_100309.xml","form_type":"4"}},{"id":853651,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-09T20:49:21.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":24937,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest monthly over a three-year period, subject to the Reporting Person's continuous service on each vesting date."}],"balance_after":24937,"derivative":{"exercise_price":38.85,"expiration_date":"2036-03-04","underlying":"Class A Common Stock","underlying_shares":24937},"source":{"system":"sec-edgar","filing":"0001814238-26-000005","document":"form4-03092026_080317.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000181423826000005/form4-03092026_080317.xml","form_type":"4"}},{"id":881296,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64668,"kind":"person","name":"Grant Sean","position":1,"cik":"0001872792","reported_name":"Grant Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Common Stock","published_at":"2026-02-26T00:59:26.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":4949,"price":41.9839,"value":207778.3211,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":114181,"source":{"system":"sec-edgar","filing":"0001872792-26-000004","document":"form4-02262026_120222.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000187279226000004/form4-02262026_120222.xml","form_type":"4"}},{"id":881295,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-02-26T00:58:27.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":16925,"price":41.9839,"value":710577.5075,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":257163,"source":{"system":"sec-edgar","filing":"0001859453-26-000004","document":"form4-02262026_120224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000004/form4-02262026_120224.xml","form_type":"4"}},{"id":881292,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64667,"kind":"person","name":"Skelton Laurence Matthew","position":1,"cik":"0002108080","reported_name":"Skelton Laurence Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T00:53:30.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":1582,"price":41.9839,"value":66418.5298,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":64218,"source":{"system":"sec-edgar","filing":"0002108080-26-000004","document":"form4-02262026_120224.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000210808026000004/form4-02262026_120224.xml","form_type":"4"}},{"id":882264,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64743,"kind":"person","name":"Brenner Robert","position":1,"cik":"0002006910","reported_name":"Brenner Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-25T20:01:07.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":2151,"price":41.9839,"value":90307.3689,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":50947,"source":{"system":"sec-edgar","filing":"0002006910-26-000004","document":"form4-02262026_010204.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2006910/000200691026000004/form4-02262026_010204.xml","form_type":"4"}},{"id":882163,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Class A Common Stock","published_at":"2026-02-25T20:00:18.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":3117,"price":41.9839,"value":130863.8163,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":64722,"source":{"system":"sec-edgar","filing":"0001861684-26-000004","document":"form4-02262026_010213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000186168426000004/form4-02262026_010213.xml","form_type":"4"}},{"id":881343,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-25T19:57:25.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":2579,"price":41.9839,"value":108276.4781,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":45727,"source":{"system":"sec-edgar","filing":"0001733883-26-000006","document":"form4-02262026_120221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000173388326000006/form4-02262026_120221.xml","form_type":"4"}},{"id":881302,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-25T19:56:22.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":2187,"price":41.9839,"value":91818.7893,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of two (2) business days, beginning on February 23, 2026 and ending on February 24, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold to solely satisfy tax withholding obligations incurred upon vesting of restricted stock units. The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a \"sell-to-cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.005 to $42.84, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":45313,"source":{"system":"sec-edgar","filing":"0001819688-26-000005","document":"form4-02262026_120218.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000181968826000005/form4-02262026_120218.xml","form_type":"4"}},{"id":915648,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-07T01:00:15.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":137500,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":137500},"source":{"system":"sec-edgar","filing":"0001859453-26-000002","document":"form4-02062026_080211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000002/form4-02062026_080211.xml","form_type":"4"}},{"id":915647,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2026-02-07T01:00:15.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":68800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 623 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025."}],"balance_after":274088,"source":{"system":"sec-edgar","filing":"0001859453-26-000002","document":"form4-02062026_080211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000185945326000002/form4-02062026_080211.xml","form_type":"4"}},{"id":915645,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64668,"kind":"person","name":"Grant Sean","position":1,"cik":"0001872792","reported_name":"Grant Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-07T01:00:13.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001872792-26-000002","document":"form4-02062026_080209.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000187279226000002/form4-02062026_080209.xml","form_type":"4"}},{"id":915644,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64668,"kind":"person","name":"Grant Sean","position":1,"cik":"0001872792","reported_name":"Grant Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Common Stock","published_at":"2026-02-07T01:00:13.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 893 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on September 12, 2025."}],"balance_after":119130,"source":{"system":"sec-edgar","filing":"0001872792-26-000002","document":"form4-02062026_080209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000187279226000002/form4-02062026_080209.xml","form_type":"4"}},{"id":915643,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64667,"kind":"person","name":"Skelton Laurence Matthew","position":1,"cik":"0002108080","reported_name":"Skelton Laurence Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-07T01:00:11.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0002108080-26-000002","document":"form4-02062026_080207.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000210808026000002/form4-02062026_080207.xml","form_type":"4"}},{"id":915642,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64667,"kind":"person","name":"Skelton Laurence Matthew","position":1,"cik":"0002108080","reported_name":"Skelton Laurence Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-07T01:00:11.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":65800,"source":{"system":"sec-edgar","filing":"0002108080-26-000002","document":"form4-02062026_080207.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000210808026000002/form4-02062026_080207.xml","form_type":"4"}},{"id":916134,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T20:00:16.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":20000,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001861684-26-000002","document":"form4-02062026_080213.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000186168426000002/form4-02062026_080213.xml","form_type":"4"}},{"id":916133,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Class A Common Stock","published_at":"2026-02-06T20:00:16.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":67839,"source":{"system":"sec-edgar","filing":"0001861684-26-000002","document":"form4-02062026_080213.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000186168426000002/form4-02062026_080213.xml","form_type":"4"}},{"id":915656,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T20:00:09.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001819688-26-000002","document":"form4-02062026_080205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000181968826000002/form4-02062026_080205.xml","form_type":"4"}},{"id":915655,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-06T20:00:09.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":47500,"source":{"system":"sec-edgar","filing":"0001819688-26-000002","document":"form4-02062026_080205.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000181968826000002/form4-02062026_080205.xml","form_type":"4"}},{"id":915680,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T20:00:07.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001733883-26-000002","document":"form4-02062026_080203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000173388326000002/form4-02062026_080203.xml","form_type":"4"}},{"id":915679,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64675,"kind":"person","name":"JOHNSON DAVID LEE","position":1,"cik":"0001733883","reported_name":"JOHNSON DAVID LEE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-06T20:00:07.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 643 shares of Class A Common Stock acquired on March 13, 2025 and 763 shares of Class A Common Stock acquired on September 12, 2025 under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":48306,"source":{"system":"sec-edgar","filing":"0001733883-26-000002","document":"form4-02062026_080203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1733883/000173388326000002/form4-02062026_080203.xml","form_type":"4"}},{"id":916211,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64743,"kind":"person","name":"Brenner Robert","position":1,"cik":"0002006910","reported_name":"Brenner Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-06T20:00:06.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the stock option will vest and become exercisable on March 4, 2026, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":42.74,"expiration_date":"2036-02-03","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0002006910-26-000002","document":"form4-02062026_080201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2006910/000200691026000002/form4-02062026_080201.xml","form_type":"4"}},{"id":916210,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64743,"kind":"person","name":"Brenner Robert","position":1,"cik":"0002006910","reported_name":"Brenner Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-06T20:00:06.000Z","date":"2026-02-04","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of Class A Common Stock underlying the restricted stock units (\"RSUs\") granted under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continuous service through each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 624 shares of Class A Common Stock acquired under the Issuer's 2021 Employee Stock Purchase Plan on March 13, 2025."}],"balance_after":53098,"source":{"system":"sec-edgar","filing":"0002006910-26-000002","document":"form4-02062026_080201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2006910/000200691026000002/form4-02062026_080201.xml","form_type":"4"}},{"id":964071,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-17T16:05:09.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date."}],"balance_after":245000,"derivative":{"exercise_price":15.53,"expiration_date":"2034-01-04","underlying":"Class A Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-25-322691","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525322691/ownership.xml","form_type":"4"}},{"id":964070,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-17T16:05:09.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":50.0767,"value":500767.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $50.00 to $50.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001193125-25-322691","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525322691/ownership.xml","form_type":"4"}},{"id":964069,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-17T16:05:09.000Z","date":"2025-12-15","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":15.53,"value":155300.0,"ownership":{"direct":true},"balance_after":32500,"source":{"system":"sec-edgar","filing":"0001193125-25-322691","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525322691/ownership.xml","form_type":"4"}},{"id":969101,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-12-16T01:07:34.000Z","date":"2025-12-11","kind":"purchase","planned":false,"acquired":true,"shares":5882,"price":42.5,"value":249985.0,"ownership":{"direct":true},"balance_after":5882,"source":{"system":"sec-edgar","filing":"0001193125-25-319649","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253886/000119312525319649/ownership.xml","form_type":"4"}},{"id":973854,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-10T16:05:05.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date."}],"balance_after":255000,"derivative":{"exercise_price":15.53,"expiration_date":"2034-01-04","underlying":"Class A Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-25-314156","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525314156/ownership.xml","form_type":"4"}},{"id":973853,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-10T16:05:05.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":45.3053,"value":453053.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $45.00 to $45.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001193125-25-314156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525314156/ownership.xml","form_type":"4"}},{"id":973852,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-10T16:05:05.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":15.53,"value":155300.0,"ownership":{"direct":true},"balance_after":32500,"source":{"system":"sec-edgar","filing":"0001193125-25-314156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525314156/ownership.xml","form_type":"4"}},{"id":979882,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-04T16:05:47.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option vested on January 5, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date."}],"balance_after":265000,"derivative":{"exercise_price":15.53,"expiration_date":"2034-01-04","underlying":"Class A Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-25-308074","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525308074/ownership.xml","form_type":"4"}},{"id":979881,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-04T16:05:47.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":40,"value":400000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 20, 2025."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001193125-25-308074","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525308074/ownership.xml","form_type":"4"}},{"id":979880,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64669,"kind":"person","name":"Turner William D.","position":1,"cik":"0001819688","reported_name":"Turner William D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Regulatory Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-04T16:05:47.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":15.53,"value":155300.0,"ownership":{"direct":true},"balance_after":32500,"source":{"system":"sec-edgar","filing":"0001193125-25-308074","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819688/000119312525308074/ownership.xml","form_type":"4"}},{"id":986660,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":16123,"kind":"person","name":"Meyers James R","position":1,"cik":"0001387521","reported_name":"Meyers James R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-26T21:37:03.000Z","date":"2025-11-25","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option will vest monthly over a three-year period subject to the Reporting Person's continuous service on each vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":25000,"derivative":{"exercise_price":29.43,"expiration_date":"2035-11-24","underlying":"Class A Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-25-300677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387521/000119312525300677/ownership.xml","form_type":"4"}},{"id":988965,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":72596,"kind":"person","name":"Carter Jason S","position":1,"cik":"0002045094","reported_name":"Carter Jason S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Class A Common Stock","published_at":"2025-11-25T16:05:05.000Z","date":"2025-11-21","kind":"sale","planned":false,"acquired":false,"shares":3864,"price":27.8204,"value":107498.0256,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.19 to $28.035, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":49136,"source":{"system":"sec-edgar","filing":"0001193125-25-297161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2045094/000119312525297161/ownership.xml","form_type":"4"}},{"id":1000411,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-13T20:57:37.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares subject to the option vest on March 9, 2022, and 1/48 of the shares vest monthly thereafter."}],"balance_after":48589,"derivative":{"exercise_price":3.9396,"expiration_date":"2031-04-13","underlying":"Class A Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-25-280792","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000119312525280792/ownership.xml","form_type":"4"}},{"id":1000410,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Class A Common Stock","published_at":"2025-11-13T20:57:37.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":3.9396,"value":39396.0,"ownership":{"direct":true},"balance_after":57839,"source":{"system":"sec-edgar","filing":"0001193125-25-280792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000119312525280792/ownership.xml","form_type":"4"}},{"id":1000409,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":60674,"kind":"person","name":"Young Joseph R","position":1,"cik":"0001861684","reported_name":"Young Joseph R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, FINANCE, CHIEF ACCT OFFCR"}}],"security":"Class A Common Stock","published_at":"2025-11-13T20:57:37.000Z","date":"2025-11-11","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":29.0583,"value":435874.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $29.17, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 893 ordinary shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan."}],"balance_after":47839,"source":{"system":"sec-edgar","filing":"0001193125-25-280792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861684/000119312525280792/ownership.xml","form_type":"4"}},{"id":1101588,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-26T00:07:16.000Z","date":"2025-06-24","kind":"purchase","planned":false,"acquired":true,"shares":27071,"price":22.3517,"value":605082.8707,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Longitude Venture Partners IV, L.P (\"LVPIV\"). Longitude Capital Partners IV, LLC (\"LCPIV\") is the general partner of LVPIV and may be deemed to have voting and dispositive power over the shares held by LVPIV. The Reporting Person and Ms. Tammenoms Bakker are managing members of LCPIV and may be deemed to share voting and dispositive power with respect to the shares held by LVPIV. Each of LCPIV, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":3596593,"source":{"system":"sec-edgar","filing":"0000950170-25-090110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1253886/000095017025090110/ownership.xml","form_type":"4"}},{"id":1101587,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-26T00:07:16.000Z","date":"2025-06-24","kind":"purchase","planned":false,"acquired":true,"shares":13536,"price":22.3517,"value":302552.6112,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Longitude Prime Fund, L.P. (\"LPF\"). Longitude Prime Partners, LLC (\"LPP\") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1797619,"source":{"system":"sec-edgar","filing":"0000950170-25-090110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1253886/000095017025090110/ownership.xml","form_type":"4"}},{"id":1101586,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-26T00:07:16.000Z","date":"2025-06-23","kind":"purchase","planned":false,"acquired":true,"shares":139595,"price":20.8683,"value":2913110.3385,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by Longitude Venture Partners IV, L.P (\"LVPIV\"). Longitude Capital Partners IV, LLC (\"LCPIV\") is the general partner of LVPIV and may be deemed to have voting and dispositive power over the shares held by LVPIV. The Reporting Person and Ms. Tammenoms Bakker are managing members of LCPIV and may be deemed to share voting and dispositive power with respect to the shares held by LVPIV. Each of LCPIV, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":3569522,"source":{"system":"sec-edgar","filing":"0000950170-25-090110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1253886/000095017025090110/ownership.xml","form_type":"4"}},{"id":1101585,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-26T00:07:16.000Z","date":"2025-06-23","kind":"purchase","planned":false,"acquired":true,"shares":69798,"price":20.8683,"value":1456565.6034,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by Longitude Prime Fund, L.P. (\"LPF\"). Longitude Prime Partners, LLC (\"LPP\") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1784083,"source":{"system":"sec-edgar","filing":"0000950170-25-090110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253886/000095017025090110/ownership.xml","form_type":"4"}},{"id":1145019,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":847,"kind":"person","name":"ENRIGHT PATRICK G","position":1,"cik":"0001253886","reported_name":"ENRIGHT PATRICK G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:13:01.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013421","document":"form4-05162025_080556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253886/000141588925013421/form4-05162025_080556.xml","form_type":"4"}},{"id":1144646,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":276,"kind":"person","name":"Oliger Christy J.","position":1,"cik":"0001822092","reported_name":"Oliger Christy J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:12:06.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013420","document":"form4-05162025_080502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1822092/000141588925013420/form4-05162025_080502.xml","form_type":"4"}},{"id":1145028,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":44157,"kind":"person","name":"MORRISSEY MICHAEL","position":1,"cik":"0001202096","reported_name":"MORRISSEY MICHAEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:11:14.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013419","document":"form4-05162025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1202096/000141588925013419/form4-05162025_080509.xml","form_type":"4"}},{"id":1145047,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":13954,"kind":"person","name":"SEIDENBERG BETH C","position":1,"cik":"0001184592","reported_name":"SEIDENBERG BETH C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:10:20.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013417","document":"form4-05162025_080516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1184592/000141588925013417/form4-05162025_080516.xml","form_type":"4"}},{"id":1145665,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":44273,"kind":"person","name":"Hall Kimball","position":1,"cik":"0001897965","reported_name":"Hall Kimball","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:08:37.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013415","document":"form4-05162025_080530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1897965/000141588925013415/form4-05162025_080530.xml","form_type":"4"}},{"id":1144727,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":34850,"kind":"person","name":"Morrison Scott W","position":1,"cik":"0001662426","reported_name":"Morrison Scott W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:06:33.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013412","document":"form4-05162025_080528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662426/000141588925013412/form4-05162025_080528.xml","form_type":"4"}},{"id":1144662,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":23608,"kind":"person","name":"Cheng Andrew","position":1,"cik":"0001778307","reported_name":"Cheng Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T20:05:20.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013408","document":"form4-05162025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1778307/000141588925013408/form4-05162025_080509.xml","form_type":"4"}},{"id":1144701,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":79666,"kind":"person","name":"Katabi Maha","position":1,"cik":"0001720685","reported_name":"Katabi Maha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T16:13:51.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control."}],"balance_after":14000,"derivative":{"exercise_price":21.19,"expiration_date":"2035-05-13","underlying":"Class A Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001415889-25-013423","document":"form4-05162025_080547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720685/000141588925013423/form4-05162025_080547.xml","form_type":"4"}},{"id":1240025,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-02-27T21:05:29.000Z","date":"2025-02-26","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":28.3183,"value":31150.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.25 to $28.42, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":204665,"source":{"system":"sec-edgar","filing":"0001415889-25-005841","document":"form4-02272025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925005841/form4-02272025_090225.xml","form_type":"4"}},{"id":1240024,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-02-27T21:05:29.000Z","date":"2025-02-26","kind":"sale","planned":true,"acquired":false,"shares":7975,"price":27.5526,"value":219731.985,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.24 to $28.21, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":205765,"source":{"system":"sec-edgar","filing":"0001415889-25-005841","document":"form4-02272025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925005841/form4-02272025_090225.xml","form_type":"4"}},{"id":1240023,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":10070,"kind":"person","name":"Fordyce Marshall","position":1,"cik":"0001859453","reported_name":"Fordyce Marshall","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Class A Common Stock","published_at":"2025-02-27T21:05:29.000Z","date":"2025-02-21","kind":"sale","planned":true,"acquired":false,"shares":10613,"price":27.8933,"value":296031.5929,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The trading order for shares sold to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) of all participants for the Issuer, including the Reporting Person, occurred over a period of three (3) business days, beginning on February 21, 2025 and ending on February 25, 2025."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"Pursuant to Rule 16a-3(g)(2) and (3)."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold to cover tax withholding obligations associated with the vesting of RSUs pursuant to an election intended to satisfy the conditions of Rule 10b5-1(c) made by the Reporting Person on August 26, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.37 to $29.80, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":213740,"source":{"system":"sec-edgar","filing":"0001415889-25-005841","document":"form4-02272025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925005841/form4-02272025_090225.xml","form_type":"4"}},{"id":1254773,"issuer":{"id":4358,"kind":"organization","name":"Vera Therapeutics, Inc.","symbol":"VERA"},"owners":[{"id":64668,"kind":"person","name":"Grant Sean","position":1,"cik":"0001872792","reported_name":"Grant Sean","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T21:08:57.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":53800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":53800,"derivative":{"exercise_price":29.18,"expiration_date":"2035-02-17","underlying":"Class A Common Stock","underlying_shares":53800},"source":{"system":"sec-edgar","filing":"0001415889-25-004846","document":"form4-02202025_090254.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1831828/000141588925004846/form4-02202025_090254.xml","form_type":"4"}}],"next_cursor":"2025-02-20T21:08:57.000000Z,1254773"}